J&J Sales Hit by Biosimilars
Today's Financial Times
Regarding Remicade: "...the approval in Europe of a “biosimilar” version made by Celltrion, a South Korean group, had a dramatic impact on sales outside the US in the second quarter, which fell to $580m compared with $783m a year ago."
well, they still have Mike Scott and Steve Wickham... that's two 'boys'
Saw all three GD Chicago shows and had a wonderful time - though Jerry definitely missed.
If you are NorCal based, make sure you check out Phil's place in San Rafael.
Their Fisherman's Blues is a favorite. I agree, good stuff.
Lots of good friends, not seen in years, in Chicago.
Also watched SC on PPV, though I live in NorCal. Had the Chicago tix already when they announced the local shows and decided, for once, too much might just be enough. I loved the intermission music and took the opportunity to learn more about Neal Casal. If you say Fade Away DT is the album to have, I'll get it.
Although I did see the boys a few times earlier (first at Wnterland in '78), like you, I didn't get hooked until those troubled years in the late 80s when I saw everything I could. You may be a familiar face.
Leaving for a music Fest in Grass Valley tomorrow. I play some guitar. It is one of several we do every year that brings together old friends. As you know, it is the late night jams that we live for. Have fun at yours.
Topical: I do my best to try to ignore the larger market but this indiscriminate rise in biotech doesn't seem sustainable in the short term. I am bracing for a correction but, who cares? Long term we are winners.
... Very long HALO, NVAX, ADXS. it's been quite a year:-)
"Early attempts by clinicians to target melanoma or renal tumors with attenuated forms of Salmonella typhimurium (ST) yielded mixed results. Although the bacteria successfully reached the tumors, they appeared to do little else. Diamond’s own studies found a similar failure to cause remission by the unmodified bacterium. This occurred, in part, because PDAC tumors use two tactics to evade treatments.
First, they secrete a thick physical barrier of hyaluronan, a sugary molecule that blocks drugs from reaching tumor cells. Second, they also produce copious amounts of a potent immunosuppressive molecule named indoleamine 2, 3-dioxygenase (IDO). IDO camouflages cancer cells and prevents the immune system from recognizing and killing the tumor.
In this new study, Diamond and his colleagues engineered ST to crack these tumor defenses. The researchers transformed bacteria to carry a piece of DNA that encodes a molecule capable of blocking IDO, known as small hairpin RNA-IDO, or simply shIDO. The modified bacteria, dubbed shIDO-ST, was combined with an enzyme (PEGPH20) that digests hyaluronan, provided to City of Hope for the study by Halozyme Therapeutics. When tumors were first pretreated with PEGPH20, the modified bacteria penetrated them much more effectively. This unique combination of bacteria and the enzyme induced a very potent anti-tumor response."
I was worried about you, Sudn. Your trade has been a disaster since you posted itt On June first. ADXS fell a third. HALO continues to climb.
I do like ADXS. I don't like NWBO - no cash. Limited partnerships. Both have good technology. Meanwhile, HALO has it all; great tech, path to market for PEG clear as day, loads of cash, increasing revenues, great management.
I'm glad you got back into HALO. My advice would be to stay in :-)
ADXS is a fine company and I appreciated the head's up when it was single digits.
I have been loosely following Northwest for years, as their technology is good. I haven't looked at the recent presentations (maybe I will) but it takes much more than good technology to get me to buy. This isn't the place to post too much about that. Keep sending ideas, though. I try to look at everything. If I feel like getting into the fray about Northwest, I'll head on over to that board.
That is my sense as well. It costs very little, relative to the total R&D budget, to keep insulin developing. Unlike the cellulite treatment, there is real potential for partnership someday with insulin. My bet is that Hylenex use in pumps will find a partner before PEG comes to market. It will be like found money.
Some of the first users of an Ebola vaccine will be the health care workers who put their own lives in danger. They will be much easier to vaccinate with Merck's vaccine than the greater population,. So, WHO will push this through as fast as possible. Eventually, though, I agree that the cold storage issue will make it a secondary option.
Speaking to your valuation comment; I agree that efficacy should not be much of an issue. But it is easy to forget the other half of the equation, safety. Giving anything to pregnant women gives regulators the shivers. If the Ph3 shows any hint of any side effect, or there is any little difference in infant measures, approval could easily be side-tracked.
almost spit out my coffee laughing!
I was pondering what he brings as I read your comment.
My guess is that this is payback to him, from one of our hedgie backers, for other considerations.
Bill and Hillary earned $180 million in 2014. That didn't come from speaking engagements or her salary as Sec of State. Of course, Tom Ridge has many conections and a quality mind. But why a cancer biotech? Because someone like Adage, believes Mr Ridge can do very well here.
correction: should read $180 million since leaving White House
Does anyone know if their shares were converted from preferred at the IPO or did they purchase them?
Also, why the ticker LIFE? Didn't that belong to a different, unrelated, company? A quick search of Yahoo's insider transactions shows data on a company run by Lucier Yahoo mistake, right?
....just doing my quarterly inspection of new cos and there is a lot here to intrigue. Seems expensive, though, and top heavy with management, for this stage of clinical development.
Thanks for sharing whatever you know.
You are absolutely correct. Upon rejection, the bidding company could become "hostile" and make their bid known to the public. They would then try to enlist large shareholders in prevailing to the BOD to negotiate further.
What do you mean "they partnered PEGph20"? They have sold NO rights to the golden goose. they are simply allowing other companies to trial HALO's drug. What more could you want?
I did, this AM. The buy is much higher than my average price, but the share price is much more likely to be 50% higher than 50% lower in six mos.
"anyone who owns this stock.." I own a ton.
Well, if you were short this week, you have done well. My investment strategies are buy and hold.
You have likely made your money off the EFT traders. Most who know this company well are holding for the long term. GLTU